Arcturus Therapeutics (NASDAQ:ARCT) just reported results for the first quarter of 2024.
- Arcturus Therapeutics reported earnings per share of -$1.00. This was above the analyst estimate for EPS of -$1.19.
- The company reported revenue of $38.01 million.
- This was 116.72% better than the analyst estimate for revenue of $17.54 million.